C.R. Bard Closes Federal Cancer Treatment Beef for $51 Million
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
C.R. Bard closes the deal it made last year with federal authorities to settle a probe into its brachytherapy cancer treatment business in return for a $51 million payment. C.R. Bard (NYSE:BCR) said it closed a deal reached last year with federal prosecutors to settle a probe into its brachytherapy business with a $51 million payment. The U.S. Health & Human Services Dept. subpoenaed Murray Hills, N.J.-based Bard in November 2006 over the cancer treatment business, under the False Claims Act and federal healthcare fraud statutes, according to regulatory filings.
Help employers find you! Check out all the jobs and post your resume.
C.R. Bard closes the deal it made last year with federal authorities to settle a probe into its brachytherapy cancer treatment business in return for a $51 million payment. C.R. Bard (NYSE:BCR) said it closed a deal reached last year with federal prosecutors to settle a probe into its brachytherapy business with a $51 million payment. The U.S. Health & Human Services Dept. subpoenaed Murray Hills, N.J.-based Bard in November 2006 over the cancer treatment business, under the False Claims Act and federal healthcare fraud statutes, according to regulatory filings.
Help employers find you! Check out all the jobs and post your resume.